Immune protein enabled resistance to anti-androgen therapy, and targeting this protein may be effective in the treatment of castrate-resistant prostate cancer.
Cancer Immunotherapy
Cancer immunotherapy is a new advancement in cancer treatment that uses certain components of a person's immune system to fight against cancer cells.
Cancer immunotherapy is a new advancement in cancer treatment that uses certain components of a person's immune system to fight against cancer cells.
‘Immune protein enabled resistance to anti-androgen therapy, and targeting this protein may be effective in the treatment of castrate-resistant prostate cancer.
’
The new study found that blocking a protein produced by a type of immune cell - known as granulocytic myeloid-derived suppressor cells - restored sensitivity to hormone therapy. Drugs that block this protein, called IL-23, already exist and are used for autoimmune diseases such as the skin condition psoriasis.
Clinical trials are now planned to assess the possible benefit of this new form of immunotherapy alongside the next-generation hormone therapy enzalutamide, in men with advanced prostate cancer.
Prostate Cancer: Treatment Options - Surgery, Radiation Therapy, Hormone Therapy
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, chemotherapy, cryosurgery or biologic therapy.
Treatment options of prostate cancer includes waiting, surgery, radiation, hormone therapy, chemotherapy, cryosurgery or biologic therapy.
The research was supported by funders including the Prostate Cancer Foundation in the US, Prostate Cancer UK, the Movember Foundation and Cancer Research UK.
Advertisement
Quiz on Prostate Cancer
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it’s too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!
Prostate cancer is fast gaining as a common cancer form among men; more threatening since its symptoms often go unnoticed until it’s too late. This quiz tests your knowledge on prostate cancer, its diagnosis and treatment options and is as mandatory for men as the screening tests mentioned here are!
They found that blood and tumour samples from men with resistant prostate cancer contained higher levels of these suppressor immune cells and IL-23 than those from men whose cancer still responded to hormone therapy.
Advertisement
Benign Prostatic Hyperplasia Assessment | Prostate Self Assessment Calculator
Benign Prostatic Hyperplasia Assessment or Prostate Self Assessment Calculator assesses the symptoms of enlarged prostate gland and gives an early warning for benign prostatic hyperplasia.
Benign Prostatic Hyperplasia Assessment or Prostate Self Assessment Calculator assesses the symptoms of enlarged prostate gland and gives an early warning for benign prostatic hyperplasia.
It also took longer for the prostate tumours to become resistant to hormone therapy, and the mice survived for a longer period of time. Both blocking IL-23 and stopping suppressor cells from moving into the tumour led to an improved response to hormone therapy, giving the researchers confidence that they identified a key mechanism that drives hormone therapy resistance in prostate cancer.
The researchers believe that IL-23 allows prostate cancer cells to sidestep the need for androgen hormones to fuel their growth.
Other immunotherapies, which work by reactivating the immune system's ability to recognise and kill cancer cells, have shown some promise in prostate cancer, but only a subset of men respond well.
As myeloid-derived suppressor cells are present in many prostate tumours, the researchers believe that this immunotherapy approach could work in a large proportion of men with the disease.
Professor Johann de Bono, Regius Professor of Cancer Research at The Institute of Cancer Research, London, and Consultant Medical Oncologist at The Royal Marsden NHS Foundation Trust, said:
"Hormone therapy works well in men with prostate cancer, but when cancer evolves to become resistant to treatment, other options are greatly reduced.
"Our study found an important interaction between hormone signalling and the immune system. We believe we could exploit this to reverse hormone resistance in prostate cancer, and boost the effect of widely used prostate cancer drugs such as enzalutamide.
"We are keen to start clinical trials to investigate how we can combine this new form of immunotherapy with existing hormone therapies, to improve treatment for men with advanced prostate cancer."
Professor Andrea Alimonti, Professor of Oncology at the University of Italian Switzerland and Institute of Oncology Research (IOR), Bellinzona, Switzerland, said:
"When we discovered that IL23 producing-MDSCs were the main immune subset infiltrating prostate tumors that have acquired resistance to hormone-treatment, we immediately realised that these cells could be one of the cause behind the emergence of castration-resistant prostate cancer.
"This study describes a new unexpected mechanism by which the tumor immune response supports the growth of prostate cancer and it opens the way for future novel therapeutic applications for the treatment of metastatic prostate cancer patients." Professor Paul Workman, Chief Executive of The Institute of Cancer Research, London, said:
"Immunotherapies have shown great promise in many cancer types, but so far their benefit in prostate cancer has been limited to a small subset of men. "This new study has uncovered a completely new way to modify the immune system to combat prostate cancer.
"A combination of hormone therapy with this new form of immunotherapy could be a really exciting new avenue of treatment for advanced prostate cancer, and it's important this approach is tested in clinical trials."
Source-Eurekalert
